Abstract:Background: Diffuse Large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma and most patients can be cured under immune-chemotherapy. One third of patients will relapse and acquired resistance to chemotherapy and turned to uncurable. The identification of biomarkers of clinical behavior may aid in the implementation of novel therapeutic strategies. OTUD7B is a deubiquitinase and is a pivotal regulator of the noncanonical NF-κB pathway. The deficiency of OTUD7B can activate the noncanonical NF-κB pathway and mediate important biological functions, including lymphoid organogenesis, B lymphocyte function, and cell growth and survival. Activation of NF-κB pathway has been an adverse prognostic index in DLBCL. The prognostic value of OTUD7B expression in lymphoma patients remains unclear. We conducted a retrospective study to investigate the impact of OTUD7B expression in DLBCL patients. Methods: Histologically confirmed DLBCL patients (N=100) treated at Fudan University Shanghai Cancer Center with available diagnostic biopsy material were identified. Forty-two patients were treated with CHOP and fifty-eight patients with R-CHOP. OTUD7B expression was determined and quantified by immunohistochemistry (IHC) with the percentage of positive cells. Tumors were considered positive when at least 20% of tumor cells expressed OTUD7B. Kaplan-Meier method was used to calculate progression free survival (PFS) and overall survival (OS) and curves were compared with the long-rank test in both groups. Correlation between the OTUD7B expression and clinical variables were tested by Pearson Chi Square test and a two-sided P value of <0.05 was considered to be statistically significant. Result: the OTUD7B expression was detected in 79/100(79%) DLBCL patients and 21% patients shown OTUD7B deficiency. It seems the OTUD7B positive patients had a better outcome, But there was no significance (p=0.107), The PFS and OS were 81% and 85% in OTUD7B positive group and 67% and 72% in OTUD7B negative group. In patients treated with CHOP regimen, the OTUD7B deficiency was associated with a worse PFS compared with OTUD7B positive patients (20% vs 78%, p=0.004). the OS of OTUD7B deficiency patients also shown a worse trend compared with the positive group (40% vs 79%, p=0.057). In patients treated with R-CHOP regimen, it is surprising, no differences between the OTUD7B positive group and negative groups were observed in terms of PFS or OS. Rituximab may overcome this worse effect caused by OTUD7B deficiency. The OTUD7B deficiency were 15% in GCB patients and 25% in non-GCB patients (p=0.31). The basic characteristics were no difference between OTUD7B positive and negative groups. Conclusion: This is the first report demonstrating that, OTUD7B deficiency is a negative predictor of clinical outcome. OTUD7B is a potential novel target to treat lymphoma and further investigation of OTUD7B need to be done in the near future. (Research supported by National Natural Science Foundation of China (no.81670177, no.81001048).

Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB

Deubiquitinase Otud7b Is Potential Prognostic Biomarker In Diffuse Large B-Cell Lymphoma

Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis

OTUD7B and NIK Expression in Non-Small Cell Lung Cancer: Association with Clinicopathological Features and Prognostic Implications.

OTUD6B promotes cholangiocarcinoma growth by regulating STAT3 phosphorylation through deubiquitination of PTK2

Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway

Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1

OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs

The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer

OTUD7B Promotes Cell Migration and Invasion, Predicting Poor Prognosis of Gastric Cancer

Deubiquitinase OTUD7B regulates cell proliferation in breast cancer

Abstract P4-03-14: OTULIN promotes resistance and metastasis upon chemotherapy in TNBC by activating Wnt/β-catenin signaling

Function of OTUD7B in acute myeloid leukemia cells and its mechanism

Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1

OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity

Abstract 4112: OTULIN promotes Wnt/β-Catenin activation by genotoxic treatments and enhances drug-resistance in breast cancer

The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients

Deubiquitinating enzyme OTUD4 stabilizes RBM47 to induce ATF3 transcription: a novel mechanism underlying the restrained malignant properties of ccRCC cells

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.